Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder

Ane Korff, Xiaojing Yang, Ozan Ozdemir, Ananya Samanta, Yong-Dong Wang, Tushar Patni, Alfonso J. Lav / science - Science Translational Medicine, Volume 18, Issue 846, April 2026.

AI Summary: Researchers report that antisense oligonucleotide therapy reversed neurological deficits in mouse models of HNRNPH2‑related neurodevelopmental disorder. The preclinical results provide a targeted mechanism to correct pathogenic RNA processing, moving a once‑untreatable condition toward a plausible therapeutic path — pending the usual caution about translating mice to humans.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 15 days

MYC overactivity enables DNA repair and chemotherapy resistance in tumours / 13 days

Mega‑analysis maps how psychedelics change brain networks / 7 wks

Pediatricians’ immune cells yield antibody cocktail protecting against RSV and hMPV / 3 months

Gene therapy restores hearing in about 90% of trial participants / 5 wks

Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 43 hrs

Stem cells show potent promise as a diabetes treatment / 8 days